Table 2.
Series | Patients, n | Conditioning | Graft source | Follow-up, y | Median age, y | Survival (PFS or DFS), % | Comment |
---|---|---|---|---|---|---|---|
Brunstein, Blood 2010,66 leukemia | 128 | Myelo | UCB | 5 | 25 | 51 | UCB similar to MRD, MUD |
204 | Ablative | MRD | 40 | 33 | |||
152 | MUD | 31 | 48 | ||||
52 | MMUD | 31 | 38 | ||||
Ponce, BBMT 2011,67 heme malignancy | 75 | Myelo | UCBT | 2 | 37 | 55 | UCB similar to MUD |
108 | Ablative | MRD | 47 | 66 | |||
184 | MUD | 48 | 55 | ||||
Brunstein, Blood 2011,69 leukemia and lymphoma | 50 | RIC | UCB | 1 | 58 | 46 | Now a randomized Clinical Trials Network study |
50 | haplo BM | 48 | 48 | ||||
Chen, BBMT 2012,68 hematologic malignancy | 64 | RIC | dUCB | 3 | 53 | 30 | UCB similar to MUD |
221 | MUD | 58 | 40 |
PFS, progression-free survival.